Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer.
ALK
BRAF
EGFR
NSCLC
ROS1
clinical trials
targeted therapy
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
09 Nov 2020
09 Nov 2020
Historique:
received:
12
10
2020
revised:
01
11
2020
accepted:
05
11
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
14
11
2020
Statut:
epublish
Résumé
Lung cancers contribute to the greatest number of cancer-related deaths worldwide and still pose challenges in response to current treatment strategies. Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers diagnosed in the United States and novel therapeutics are needed for the treatment of this disease. First and second generation targeted therapies against specific mutated or rearranged oncogenes in NSCLCs show anti-tumor activity and also increase survival. However, many NSCLC patients eventually develop resistance to these therapies or do not properly respond if they have central nervous system metastases. Thus, this review summarizes recent developments and findings related to the generation of novel targeted therapies recently or currently being developed to tackle hurdles that prior therapies were not able to overcome.
Identifiants
pubmed: 33182254
pii: ph13110374
doi: 10.3390/ph13110374
pmc: PMC7695293
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Infect Public Health. 2012 Dec;5 Suppl 1:S50-60
pubmed: 23244189
Mol Cancer. 2018 Feb 19;17(1):52
pubmed: 29455675
J Thorac Oncol. 2016 Jul;11(7):e83-5
pubmed: 26988570
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Clin Cancer Res. 2019 Dec 15;25(24):7312-7319
pubmed: 31416808
Transl Lung Cancer Res. 2015 Apr;4(2):110-8
pubmed: 25870793
Ann Oncol. 2019 Jul 1;30(7):1121-1126
pubmed: 30980071
Cancers (Basel). 2017 Sep 05;9(9):
pubmed: 28872581
Adv Ther. 2020 Jun;37(6):3019-3030
pubmed: 32399810
Ann Transl Med. 2017 Oct;5(19):388
pubmed: 29114546
Ann Palliat Med. 2020 Sep;9(5):3038-3047
pubmed: 32954743
Lung Cancer. 2020 Mar;141:114-118
pubmed: 31839416
Int J Mol Sci. 2019 Jan 03;20(1):
pubmed: 30609789
BMC Cancer. 2019 Mar 28;19(1):280
pubmed: 30922269
J Clin Oncol. 2017 May 1;35(13):1403-1410
pubmed: 28447912
J Clin Oncol. 2020 Nov 1;38(31):3592-3603
pubmed: 32780660
JAMA. 2019 Aug 27;322(8):764-774
pubmed: 31454018
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33020239
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Curr Oncol Rep. 2020 Apr 16;22(5):48
pubmed: 32296961
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Sci Rep. 2020 Jun 25;10(1):10387
pubmed: 32587276
J Neurosci. 2016 Oct 5;36(40):10425-10439
pubmed: 27707976
Ann Oncol. 2020 Feb;31(2):289-294
pubmed: 31959346
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Eur Respir J. 2009 Jun;33(6):1485-97
pubmed: 19483050
J Thorac Oncol. 2020 Jan;15(1):50-61
pubmed: 31557536
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935770
pubmed: 32600123
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Lung Cancer (Auckl). 2019 Sep 09;10:87-94
pubmed: 31572036
J Thorac Oncol. 2015 Mar;10(3):486-91
pubmed: 25695221
Cells. 2018 Nov 15;7(11):
pubmed: 30445769
Int J Mol Sci. 2020 Apr 19;21(8):
pubmed: 32325863
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Thorac Oncol. 2017 Aug;12(8):e107-e110
pubmed: 28502724
Cancer Manag Res. 2019 May 07;11:4109-4118
pubmed: 31190983
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Expert Rev Anticancer Ther. 2016 Jun;16(6):615-23
pubmed: 27109446
Lung Cancer. 2019 Jul;133:96-102
pubmed: 31200835
Cancers (Basel). 2020 Mar 28;12(4):
pubmed: 32231067
J Thorac Oncol. 2020 Apr;15(4):601-608
pubmed: 31712133
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
J Thorac Oncol. 2020 Feb;15(2):258-265
pubmed: 31669591
Clin Cancer Res. 2020 Jul 1;26(13):3287-3295
pubmed: 32269053
Cell Tissue Res. 2018 May;372(2):325-337
pubmed: 29374774
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
Eur Respir J. 2015 Apr;45(4):1132-41
pubmed: 25700389
Lancet Respir Med. 2020 Jan;8(1):45-53
pubmed: 31628085
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
J Thorac Oncol. 2020 Oct;15(10):1611-1623
pubmed: 32540409
Lancet Oncol. 2014 Oct;15(11):1236-44
pubmed: 25175099
Drugs Context. 2019 Mar 13;8:212566
pubmed: 30899313
Expert Rev Respir Med. 2019 Nov;13(11):1095-1107
pubmed: 31512526
Clin Cancer Res. 2018 Jun 15;24(12):2771-2779
pubmed: 29563138
Cancer Discov. 2020 May;10(5):643-645
pubmed: 32357968
J Clin Oncol. 2020 Jul 1;38(19):2140-2150
pubmed: 32182156
Br J Cancer. 2020 Oct 5;:
pubmed: 33012782
Sci Rep. 2019 Mar 19;9(1):4844
pubmed: 30890751
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
Cancer Discov. 2018 Jun;8(6):686-695
pubmed: 29610121
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Eur J Cancer. 2020 Jun;132:211-223
pubmed: 32388065
Eur Respir J. 2020 Feb 6;55(2):
pubmed: 32029641
Lancet Oncol. 2016 May;17(5):642-50
pubmed: 27080216
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
pubmed: 15741570
J Thorac Oncol. 2017 Jul;12(7):e85-e88
pubmed: 28274743
Lancet Oncol. 2019 Dec;20(12):1691-1701
pubmed: 31669155
J Clin Oncol. 2020 Feb 10;38(5):488-495
pubmed: 31825714
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Clin Cancer Res. 2013 Aug 15;19(16):4532-40
pubmed: 23833300
Clin Cancer Res. 2020 Sep 15;26(18):4785-4794
pubmed: 32591465
Curr Oncol. 2019 Aug;26(4):e551-e557
pubmed: 31548824
Lancet Oncol. 2020 Feb;21(2):261-270
pubmed: 31838015